摘要
目的探讨卡培他滨腹腔热灌注化疗(HIPEC)在进展期结直肠癌患者中的应用效果.方法选取2017年2月-2021年2月天津海滨人民医院收治的150例进展期结直肠癌患者,按随机数字表法分成两组,每组各75例.对照组给予根治手术治疗,观察组加用卡培他滨HIPEC治疗,持续观察至术后1个月,并随访12个月.对比两组疾病控制效果、免疫功能、血清肿瘤标志物、肿瘤转移率及复发率.结果观察组疾病控制率93.33%,高于对照组的78.67%,有统计学差异(P<0.05);治疗前两组免疫功能、血清肿瘤标志物比较,无统计学差异(P>0.05);术后1个月,观察组CD3^(+)水平(63.12±5.91)%、CD4^(+)水平(39.55±4.25)%、CD4^(+)/CD8^(+)水平(2.24±0.33),分别高于对照组的(58.30±4.23)%、(34.75±3.71)%、(1.83±0.25);观察组CD8^(+)水平(23.10±2.43)%、糖链抗原19-9(CA19-9)水平(37.52±4.49)kU/mL、糖类抗原125(CA125)水平(21.17±3.95)μg/L、癌胚抗原(CEA)水平(49.65±8.15)μg/L,分别低于对照组的(26.29±2.52)%、(43.14±4.58)kU/mL、(27.16±3.81)μg/L、(60.73±9.69)μg/L;肿瘤转移率2.67%、复发率4.00%,分别低于对照组的13.33%、16.00%,有统计学差异(P<0.05).结论卡培他滨HIPEC能增强进展期结直肠癌患者疾病控制效果与身体免疫功能,降低血清肿瘤标志物水平,从而减少肿瘤转移及复发.
Objective To investigate the effect of capecitabine intraperitoneal thermal perfusion chemotherapy(HIPEC)in patients with advanced colorectal cancer.Methods 150 patients with advanced colorectal cancer admitted to our hospital from February 2017 to February 2021 were randomly divided into two groups with 75c ases each.The control group was treated with radical surgery,and the observation group was treated with capecitabine HIPEC.Thep atients were continuously observed for 1 month after operation and followed up for 12 months.The disease control effect,immuneu fnction,serum tumor markers,tumor metastasis rate and recurrence rate were compared between the two groups.Results The disease control rate in the observation group was 93.33%,which was higher than 78.67%in the control group(P<0.05);there was no significant difference in immune function and serum tumor markers between the two groups before treatmentP(>0.05);one month after operation,the levels of CD3^(+),CD4^(+) and CD4^(+)/CD8^(+) in the observation group were(63.12±5.91)%,(39.55±4.25)%and(2.24±0.33)%,respectively,higher than those in the control group(58.30±4.23)%,(34.75±3.71)%and(1.83±0.25);CD8^(+) level(23.10±2.43)%,carbohydrate antigen 19-9(CA19-9)level(37.52±4.49)kU/mL,carbohydrate antigen 125(CA125)level(21.17±3.95)μg/L,and carcinoembryonic antigen(CEA)level(49.65±8.15)μg/L,lower than those in the control group(26.29±2.52)%,(43.14±4.58)kU/mL,(27.16±3.81)μg/L,(60.73±9.69)μg/L.The tumor metastasis rate was 2.67%and the recurrence rate was 4.00%,which was lower than 13.33%and 16.00%of the control group P(<0.05).Conclusion Capecitabine HIPEC can enhance the effect of disease control and body immune funciotn in patients with advanced colorectal cancer,reduce the leevl of serum tumor markers,and thus reduce tumor metastasis and recurrence.
作者
庞宏欣
尹洪泉
王卫
张庆怀
Pang Hongxin;Yin Hongquan;Wang Wei;Zhang Qinghuai(Tianjin Haibin People's Hospital,Binhai New Area,Tianjin 300280,China)
出处
《首都食品与医药》
2023年第11期70-72,共3页
Capital Food Medicine
关键词
进展期结直肠癌
腹腔热灌注化疗
卡培他滨
免疫功能
血清肿瘤标志物
Advanced colorectal cancer
Intraperitoneal thermal perfusion chemotherapy
Capecitabine
immunity
Serum tumor markers
